Company profile: Clearmind Medicine
1.1 - Company Overview
Company description
- Provider of psychedelic medicine research and development, discovering and developing novel psychedelic-derived therapeutics for under-served health problems. Pipeline includes CMND-100, a MEAI-based oral capsule for Alcohol Use Disorder in Phase I/IIa, and 3-MMC for eating disorders. Holds exclusive worldwide rights to a patent-pending synthesis for addiction and mental disorders and 17 utility patent families (27 granted, 32 pending).
Products and services
- Patent Portfolio: Utility-patent-based IP portfolio encompassing 17 patent families, 27 granted patents, and 32 pending applications covering a range of psychedelic compounds and their uses
- Psychedelic Compound Synthesis: Patent-pending synthesis with exclusive worldwide rights to develop and commercialize products derived from psychedelic compounds for addiction and mental disorders
- CMND-100: Clinical-stage MEAI-based oral capsule engineered for treating Alcohol Use Disorder, currently in Phase I/IIa clinical trials.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Clearmind Medicine
Theranexus
HQ: France
Website
- Description: Provider of clinical-stage therapies for brain disorders, including Batten-1, a drug candidate targeting Batten disease by blocking glycosphingolipid accumulation and neuro-inflammation to prevent brain cell death, and NeuroLead, a discovery platform for innovative therapy candidates in rare neurological disorders developed with CEA and Collège de France.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theranexus company profile →
Oculogica
HQ: United States
Website
- Description: Provider of neuro-diagnostic medical devices and training focused on TBI, concussion, and eye-tracking. Products include EyeBOX, an FDA-cleared, baseline-free, non-invasive device that tracks eye movements to aid in concussion (mTBI) diagnosis with results in under four minutes, and OcuPro, a roadside test for law enforcement to detect recent cannabis use and impairment. Offers EyeBOX training to customers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oculogica company profile →
Aeon Biopharma
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, developing novel and proprietary treatment paradigms to improve patient outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aeon Biopharma company profile →
Compass Pathways
HQ: United Kingdom
Website
- Description: Provider of psilocybin-based mental health therapies and research for treatment-resistant depression, PTSD, and anorexia nervosa. Offers COMP360 psilocybin treatment administered with psychological support, a therapist training programme, a Discovery Center for preclinical studies, and support for investigator-initiated studies, conducting clinical trials and research on psilocybin therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Compass Pathways company profile →
NeuroPace
HQ: United States
Website
- Description: Provider of implantable neurostimulation devices for neurological disorders, featuring the FDA-approved RNS System for epilepsy to monitor brain activity, detect unusual patterns, and deliver responsive pulses to prevent seizures. Offers personalized neuromodulation based on patient brain activity, the nSight platform for remote data access, and clinical studies (NAUTILUS, RESPONSE, and other RNS System trials).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeuroPace company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Clearmind Medicine
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Clearmind Medicine
2.2 - Growth funds investing in similar companies to Clearmind Medicine
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Clearmind Medicine
4.2 - Public trading comparable groups for Clearmind Medicine
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →